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introduCtion
MRI provides a number of benefits in radiotherapy (RT) 
of the prostate, including improved soft tissue resolution 
for prostate and organs at risk delineation and multipara-
metric imaging for intraprostatic lesion identification and 
response assessment. There has been increasing interest in 
MR-guided systems1,2 to encompass these advantages and 
permit intrafractional imaging without additional radi-
ation exposure.3 With variability in prostate and seminal 
vesicles contouring dependent on the sequence used,4 
sequence optimisation is vital to maintain accuracy. In 
addition, prostate delineation must be completed in a 
timely manner when used in an online or real-time adap-
tive setting.
Dedicated MRI sequences can enhance the signal void 
of fiducials,5,6 required for accurate MRI and CT fusion7 
and position verification prior to treatment. One such 
sequence, T2*-weighted (T2*W) MRI, uses multiple echo 
times8 resulting in a more defined prostate capsule as well 
as a reliable depiction of fiducials; geometric accuracy and 
clinician contouring consistency on this type of sequence 
has previously been assessed.9
With relative unfamiliarity of MRI compared to CT, 
MRI must be introduced carefully into the RT planning 
process involving all members of the interprofessional 
team, together with appropriate training.10 Therapeutic 
radiographers at our centre are experienced in reviewing 
the prostate position on cone beam CT (CBCT) for image 
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objective: With increasing incorporation of MRI in radi-
otherapy, we investigate two MRI sequences for prostate 
delineation in radiographer-led image guidance.
Methods: Five therapeutic radiographers contoured 
the prostate individually on CT, T2 weighted (T2W) and 
T2* weighted (T2*W) imaging for 10 patients. Contours 
were analysed with Monaco ADMIRE (research v. 2.0) to 
assess interobserver variability and accuracy by compar-
ison with a gold standard clinician contour. Observers 
recorded time taken for contouring and scored image 
quality and confidence in contouring.
results: There is good agreement when comparing radi-
ographer contours to the gold-standard for all three 
imaging types with Dice similarity co-efficient 0.91–0.94, 
Cohen’s κ 0.85–0.91, Hausdorff distance 4.6–7.6 mm 
and mean distance between contours 0.9–1.2 mm. In 
addition, there is good concordance between radiog-
raphers across all imaging modalities. Both T2W and 
T2*W MRI show reduced interobserver variability and 
improved accuracy compared to CT, this was statistically 
significant for T2*W imaging compared to CT across all 
four comparison metrics. Comparing MRI sequences 
reveals significantly reduced interobserver variability 
and significantly improved accuracy on T2*W compared 
to T2W MRI for DSC and Cohen’s κ. Both MRI sequences 
scored significantly higher compared to CT for image 
quality and confidence in contouring, particularly T2*W. 
This was also reflected in the shorter time for contouring, 
measuring 15.4, 9.6 and 9.8 min for CT, T2W and T2*W 
MRI respectively.
Conclusion:
Therapeutic radiographer prostate contours are more 
accurate, show less interobserver variability and are 
more confidently and quickly outlined on MRI compared 
to CT, particularly using T2*W MRI.
advances in knowledge:
Our work is relevant for MRI sequence choice and devel-
opment of the roles of the interprofessional team in the 
advancement of MRI-guided radiotherapy.
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guidance prior to treatment delivery. RT services benefit from 
the expanded role of therapeutic radiographers including radiog-
rapher-led delineation of the target or organs at risk11 which can 
shorten the treatment planning process.12 At our institution, 
following a training programme, specialised therapeutic radiog-
raphers outline the prostate and seminal vesicles on the RT plan-
ning CT, prior to clinician review and final approval.
However, with the emergence of new technologies, this must 
be extended to prostate identification on MRI for MRI-guided 
RT. With the installation of the Elekta MR-Linac1 at our centre 
and treatment of our first patient in September 2018, we wish 
to extend the therapeutic radiographer role to include delinea-
tion of the prostate on MRI. This will be particularly relevant for 
adaptive online replanning where recontouring and intrafraction 
monitoring of the target is required.
With RT workflow changing, the work we present here addresses 
an important area which has not been well studied to date. 
Despite the evolving role of therapeutic radiographers, to our 
knowledge there are no publications demonstrating the accuracy 
and consistency of radiographer-derived contours which is an 
essential part of treatment quality assurance. Our study assesses 
the interobserver variability and accuracy of prostate delineation 
by therapeutic radiographers using three imaging types; CT, T2 
weighted (T2W) and T2*W MRI.
MethodS and MaterialS
Patient population
The patient population and image acquisition have previ-
ously been described.9 10 patients receiving treatment within 
the Prostate Advances in Comparative Evidence (PACE) trial 
(NCT01584258) at the Royal Marsden Hospital NHS Foundation 
Trust, Sutton, had RT planning CT and MRI scans acquired on 
the same day. The PACE trial has two parallel randomisations; 
PACE A randomises between prostatectomy or stereotactic body 
radiotherapy (SBRT) to a dose of 36.25 Gy in five fractions, and 
PACE B randomised patients between SBRT or conventionally 
fractionated RT, either 62 Gy in 20 fractions or 78 Gy in 39 frac-
tions. Patients do not receive androgen deprivation therapy.
Image acquisition
At least 1 week prior to planning imaging, three 1.0 × 3.0 mm 
knurled gold fiducial markers are inserted under transrectal 
ultrasound guidance. Patients are instructed regarding bladder 
filling and rectal preparation as per departmental guidelines 
prior to their imaging sessions. The latter consists of two days of 
rectal preparation with microenemas prior to their CT planning 
appointment, and an enema just before their planning CT scan. 
The treatment set-up position is replicated for planning imaging. 
The CT extends in 1.5 mm axial slices from the mid-lumbar spine 
to below the obturator foramen. This is followed, on the same 
day, by the planning MRI scan at 1.5 T (Siemens Aera, Erlangen, 
Germany) with 2 two-dimensional sequences, covering the 
prostate volume using 28 adjacent slices (at 2.5 mm thickness). 
Firstly, a standard T2W pulse sequence used in diagnostic pros-
tate MRI and based on fast spin echoes, allowing visualisation 
of the internal structure of the prostate, is acquired. The second 
sequence is T2*W combining several gradient echo signals, with 
a range of echo-times into a single image, thereby maximising 
the signal loss related to the fiducial markers. Examples of images 
are shown in Figure 1.
Contouring
The contouring and analysis methods have previously been 
described in published abstract format.13 Three clinicians 
Figure 1. A–C are examples of CT, T2W and T2*W imaging at corresponding levels for the same patient, without contours. D–F 
demonstrate the same imaging with superimposed radiographer contours. Reproduced from published abstract format with per-
mission.13
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experienced in prostate RT delineated the prostate on each of 
the three imaging data sets—CT, T2W and T2*W MRI using 
Monaco v.5.19.02 (research version, Elekta AB, Stockholm, 
Sweden). All contours were created individually, without refer-
ence to other types of imaging. A minimum of 2 weeks was 
left between contouring images of the same patient to avoid 
recall bias. A simultaneous truth and performance level esti-
mate (STAPLE)14 contour was created from all three clinician 
contours for each imaging set to create the "gold-standard" for 
comparison. The interobserver variability for these clinician 
contours has previously been reported with median Dice simi-
larity co-efficient (DSC) of 0.95 (interquartile range 0.94–0.96), 
0.97 (0.96–0.97) and 0.97 (0.96–0.97) for CT, T2W and T2*W 
imaging respectively.9
Five therapeutic radiographers experienced in delineation and/
or registration of the prostate on CT and CBCT, completed a 
single training session, delivered by a clinical oncologist. The 
training included review of the anatomy on each of the three 
imaging types and access to CT, T2W and T2*W “atlases” with 
axial contours to refer to. The radiographers then delineated the 
prostate on CT, T2W and T2*W MRI for the same 10 patients 
using the same instructions. In addition, the time taken for 
delineation was recorded and images were scored from 0 to 10 
for “image quality” and “confidence in contouring”, where a 
higher score indicates an improvement.
Analysis of contours
Assessment was made of;
(1) Interobserver variability—a STAPLE contour was created 
from the contours of all five radiographers. Each individual 
contour was then compared to this STAPLE contour to assess 
radiographer interobserver variability.
(2) Accuracy—by comparison of radiographer contours to the 
gold standard’ clinician STAPLE.
Contours were assessed using Monaco ADMIRE software v.2.0 
(research version, Elekta AB, Stockholm, Sweden). For each 
comparison, the overlap measures DSC and Cohen’s kappa (κ) 
were recorded, (where higher values indicate greater agreement). 
In addition, the distance measures of Hausdorff distance and 
mean distance between contours were recorded (where lower 
values indicate greater agreement).
Using GraphPad Prism v7.0d, non-parametric Friedman testing 
was performed with Dunn’s test for multiple comparisons. The 
three imaging comparisons—CT vs. T2W, CT vs. T2*W and T2W 
vs. T2*W were pre-planned. Values were defined as statistically 
different if the adjusted p-value was <0.05.
reSultS
Examples of radiographer contours are shown in Figure 1, repro-
duced from published abstract format with permission.13
Median (interquartile range) comparisons for each imaging type, 
delineation times and imaging scores are summarised in Table 1. 
Results of statistical testing are summarised in Figure 2.
The high overlap values, with all DSC and Cohen’s κ >0.85, illus-
trate the good agreement between radiographers and between 
radiographers and the gold-standard across all imaging types.
On comparison of MRI to CT, both T2W and T2*W contours 
show higher overlap values and lower distance values, indicating 
reduced interobserver variability and improved accuracy when 
compared to the gold standard. This was statistically significant 
for T2*W contours compared to CT across all four comparison 
metrics.
In addition, comparison of the two MRI sequences reveals that 
prostate contours delineated using T2*W MRI show signifi-
cantly decreased interobserver variability for all measurements 
excluding Hausdorff distance, and significantly improved accu-
racy for DSC and Cohen’s κ when compared to T2W MRI. 
(Table 1/ Figure 2).
Table 1. Summary of median (interquartile range) comparison values for each imaging type
CT T2W MRI T2*W MRI
Interobserver variability
DSC 0.93 (0.91–0.95) 0.94 (0.93–0.95) 0.96 (0.95–0.96)
Cohen κ 0.90 (0.87–0.91) 0.91 (0.89–0.92) 0.93 (0.92–0.94)
HD (mm) 6.5 (5.7–7.9) 4.8 (4.2–5.8) 4.7 (3.9–5.4)
Mean d (mm) 0.9 (0.8–1.1) 0.8 (0.7–1.0) 0.7 (0.6–0.7)
Comparison to gold-standard
DSC 0.91 (0.89–0.92) 0.93 (0.91–0.94) 0.94 (0.93–0.95)
Cohen κ 0.85 (0.83–0.88) 0.89 (0.86–0.90) 0.91 (0.89–0.93)
HD (mm) 7.6 (6.6–9.1) 5.2 (4.4–6.2) 4.6 (4.0–5.5)
Mean d (mm) 1.2 (1.2–1.4) 1.0 (0.9–1.2) 0.9 (0.7–1.0)
Assessment of contouring efficiency
Time taken to contour (min) 15.4 (12.0–16.3) 9.6 (8.3–12.6) 9.8 (8.9–10.9)
Image quality (0–10) 5.3 (5.2–5.8) 7.8 (7.4–8.1) 8.5 (8.2–8.8)
Confidence in contour (0–10) 5.5 (5.2–5.6) 6.8 (6.7–7.3) 7.8 (7.5–7.9)
DSC, Dice similarity co-efficient; HD, Hausdorff distance; d, distance.
Values are reported to one decimal place apart from overlap measures reported to two decimal places.
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Greater quality images and confidence in contouring were 
reported for both MRI types but especially T2*W MRI, reflected 
in the shorter time to complete contours, with a median of 
9.6–9.8 min for MRI compared to 15.4 min for CT.
diSCuSSion
We have demonstrated that despite the unfamiliarity of MRI, 
interobserver variability and accuracy of therapeutic radiogra-
pher prostate contours improved with both MRI sequences, in 
particular the T2*W sequence.
We have considered both consistency and accuracy of contours. 
The reduced interobserver variability on MRI is in keeping with 
previous results from clinician contouring15–17 as a result of 
improved soft tissue contrast, reflected in the higher scores for 
image quality and confidence in contouring. However, this was 
only statistically significant across all four measures for T2*W vs. 
CT.
For accuracy of contouring, a gold-standard for RT planning 
is difficult to define; here we have used the STAPLE of three 
Figure 2. Summary of p-values (reported to two decimal places) from statistical testing for comparison between imaging modal-
ities. Values are adjusted for multiple comparisons and statistically significant if p<0.05. Abbreviations: Cohen,Cohen’s κ; mean d, 
mean distance between contours; confid, confidence in contouring score; image, image quality score; .
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experienced clinicians to reduce the effect of interobserver vari-
ability for the gold-standard contour. All observers, both clini-
cians and radiographers, are from the same institution, which 
will influence both consistency and accuracy, as assessed by the 
overlap and distance measurements here and previously.9
With regards to time, the prostate was delineated on both MR 
sequences more quickly compared to CT. There was a reduc-
tion in the median time for contouring by 5.6 and 5.8 min for 
T2*W and T2W MRI respectively. This is particularly relevant 
for contouring in an online adaptive workflow, where short-
ening this step is beneficial to minimise intrafractional motion. 
Although the time improvement with MRI is mirrored in the 
higher confidence in contouring and image quality of MRI 
compared to CT, note must be made of the differing slice thick-
ness of the images—1.5 mm for CT and 2.5 mm for MRI. As a 
result, there were a greater number of slices over the length of 
the prostate for contouring on CT compared to MRI. Although 
observers were allowed to use interpolation of contours if desired 
on any of the image sets, the time taken must be interpreted with 
caution for this reason.
There is no consensus on the best method for contour compar-
ison,18,19 we have therefore used a combination of comparison 
values here to encompass the overlap and distance between 
contours. Although we have carried out statistical testing here, 
we have not assessed the clinical impact of a significant difference 
in these comparisons. For example, the clinical implication of a 
DSC of 0.93 vs 0.95 may be negligible although this will also be 
dependent on where the discrepancy lies and the margins added 
during planning. The resulting dosimetric effect, not assessed 
here, would be more relevant.20
Our findings are particularly important as we have commenced 
MR-guided RT at the Royal Marsden Hospital with daily online 
replanning, which requires recontouring on images acquired 
each day. The process either involves manual contouring from 
the beginning or amending propagated contours produced by 
deformable registration of the reference image to the new daily 
acquired image. To begin with, this is clinician led with the aim 
of expanding the role of our radiographers to encompass this 
step. This is an essential progression of the extended role which 
has developed from evaluating treatment portal images,21 evalu-
ating verification images for hypofractionated treatments,22 and 
to more recently, choosing the “plan of the day”.23 Accurate target 
identification is also required for motion monitoring of the target 
prostate during treatment delivery. Contributing to current liter-
ature, our study has considered the practical points of “confi-
dence in contouring” and the time taken, both highly relevant in 
the time pressured online adaptive RT setting.
Most relevant literature to date makes use of T2W images which 
are the mainstay of MRI for diagnosis and staging. We have 
proposed the T2*W sequence, which not only allows visualisa-
tion of the fiducials, particularly important for a mixed CT-MR 
workflow, but also provides improved contrast between the pros-
tate and surrounding tissues. MRI for delineation is not used 
routinely outside of a trial setting in our institution but implanted 
fiducial markers are used for image guidance prior to each 
fraction. Our study shows that sequences such as T2*W MRI, 
allowing improved prostate capsule visualisation and contour 
accuracy, can continue to be useful even if fiducials are no longer 
required, such as with the clinical use of MR only workflow.
The work we have presented here is novel, in addition to estab-
lishing the accuracy and consistency of contours for this profes-
sional group, we have demonstrated the relevance of sequence 
selection and validated the use of the T2*W sequence. Our work 
will be expanded further to assess the dosimetric impact of any 
differences in contours and consider the use of the T2*W sequence 
for automatic contouring. A formal training programme will also 
be designed for therapeutic radiographer training as the role of 
MR-guided RT develops.
ConCluSionS
Despite unfamiliarity with MRI for treatment verification, 
therapeutic radiographer prostate contours are more accurate, 
show less interobserver variability and are more confidently 
and quickly outlined on MRI compared to CT. In addition, this 
improvement is consistently statistically significant for the T2*W 
MRI sequence. This is particularly relevant for MRI sequence 
choice and development of the roles of the interprofessional team 
in the advancement of MRI-guided RT.
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